Avalo Therapeutics (AVTX) EBITDA (2014 - 2026)
Avalo Therapeutics posted quarterly EBITDA of -$19.7 million for Q1 2026, down 49.85% year-on-year from -$39.3 million in Q1 2025, and down 43.9% on a QoQ basis from -$13.7 million in Q4 2025.
Avalo Therapeutics (AVTX) has 13 years of EBITDA data on file, last reported at -$19.7 million in Q1 2026.
- For the quarter ending Q1 2026, EBITDA fell 49.85% year-over-year to -$19.7 million; the trailing twelve-month figure through Mar 2026 stood at -$84.7 million (down 216.07% YoY), and the FY2025 full-year result was -$78.2 million, down 122.58% from the prior year.
- EBITDA for Q1 2026 stood at -$19.7 million, down from -$13.7 million in the prior quarter.
- Across five years, EBITDA topped out at $98.5 million in Q2 2024 and bottomed at -$121.3 million in Q1 2024.
- The 5-year median for EBITDA is -$13.0 million (2022), against an average of -$12.0 million.
- Peak annual rise in EBITDA reached 1301.79% in 2024, while the deepest fall reached 1118.38% in 2024.
- A 5-year view of EBITDA shows it stood at -$8.9 million in 2022, then climbed by 13.52% to -$7.7 million in 2023, then tumbled by 361.47% to -$35.3 million in 2024, then jumped by 61.25% to -$13.7 million in 2025, then plunged by 43.9% to -$19.7 million in 2026.
- The last three EBITDA figures came in at -$19.7 million (Q1 2026), -$13.7 million (Q4 2025), and -$30.6 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -13.63 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -19.70 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -14.44 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.14 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.82 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 661.60 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 201.19 Mn |
| 10 | Avalo Therapeutics | 317.29 Mn | 317.29 Mn | - | -19.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -19.70 Mn |
| Dec 31, 2025 | -13.69 Mn |
| Sep 30, 2025 | -30.55 Mn |
| Jun 30, 2025 | -20.80 Mn |
| Mar 31, 2025 | -13.15 Mn |
| Dec 31, 2024 | -35.34 Mn |
| Sep 30, 2024 | 23.04 Mn |
| Jun 30, 2024 | 98.46 Mn |
| Mar 31, 2024 | -121.29 Mn |
| Dec 31, 2023 | -7.66 Mn |
| Sep 30, 2023 | -5.23 Mn |
| Jun 30, 2023 | -8.19 Mn |
| Mar 31, 2023 | -9.96 Mn |
| Dec 31, 2022 | -8.86 Mn |
| Sep 30, 2022 | 3.19 Mn |
| Jun 30, 2022 | -12.99 Mn |
| Mar 31, 2022 | -22.05 Mn |
| Dec 31, 2021 | -17.96 Mn |
| Sep 30, 2021 | -16.46 Mn |
| Jun 30, 2021 | -17.13 Mn |
| Mar 31, 2021 | -30.58 Mn |
| Dec 31, 2020 | -16.34 Mn |
| Sep 30, 2020 | -13.28 Mn |
| Jun 30, 2020 | -11.82 Mn |
| Mar 31, 2020 | -31.41 Mn |
| Dec 31, 2019 | -5.72 Mn |
| Sep 30, 2019 | -2.86 Mn |
| Jun 30, 2019 | -2.55 Mn |
| Mar 31, 2019 | -5.00 Mn |
| Dec 31, 2018 | -1.56 Mn |
| Sep 30, 2018 | -24.31 Mn |
| Jun 30, 2018 | -5.75 Mn |
| Mar 31, 2018 | -3.75 Mn |
| Dec 31, 2017 | -4.36 Mn |
| Sep 30, 2017 | 21.92 Mn |
| Jun 30, 2017 | -1.77 Mn |
| Mar 31, 2017 | -1.90 Mn |
| Dec 31, 2016 | -1.69 Mn |
| Sep 30, 2016 | -5.96 Mn |
| Jun 30, 2016 | -3.49 Mn |
| Mar 31, 2016 | -4.94 Mn |
| Dec 31, 2015 | -3.68 Mn |
| Sep 30, 2015 | -1.96 Mn |
| Jun 30, 2015 | -2.89 Mn |
| Mar 31, 2015 | -2.48 Mn |
| Dec 31, 2014 | -3.83 Mn |
| Sep 30, 2014 | -6.00 Mn |